Trial Profile
A Phase II trial of irinotecan / S-1 (IRIS) + alfa (Panitumumab/Bevacizumab) as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) A multicenter phase II trial of TS1 + Irinotecan (IRIS) + Bevacizumab as second line treatment in patients with KRAS mutant type unresectable advanced colorectal cancer (mCRC).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms IRIS-PB
- 13 Dec 2012 New trial record